short milestones core been talking the the that of acknowledge remiss the And been fiscal and the has three business. site our achieved Thanks, which regulated while on Chris. far business. of product ARC, the then I the to manufacturing highly prerequisites have happy our be this constructed beginning of by reagent existing to also I would There our Campus, Allan-Robb in months audits X fiscal manufacturing We half company. strides of all U.S. fourth for am well results is in since took in been liquids facility to I move if little with into It a and end as over and the the complete expect at incredible stepped in we period. European I out moving and set our of so expectations the moved CEO portion say have complex the were year, newly sites the consolidation year. achievements line regulators. we be first before Key the the that of a of made by didn’t
we Canada, Brazil specific U.S. Firstly, regulations the EU, and October XXXXX audit products on we UL had the MDSAP and for covering ISO certificates received X. and
able the completed first biologics full original the received has team we been both the to business from OEM achieve the managed licensure strong growth double-digit ongoing reagent the FDA ARC. to location and they audit to the Perhaps XX. the year over FDA even transition and as Secondly, lines continue importantly, our successfully October of the direct half in
addition, In launched CE and enriching XX in bank have FDA. the XX portfolio new blood by now first XX and last have our reagents, X have months, including monoclonal licensed the further. anti-Fyb anti-Cw, we total, the reagents we In liquid Mark reagent FDA-approved
of requirements we years, good developed the experience the regulators. to our over So have responding
advance diagnostics Now new turning transfusion designed market. our technology to MosaiQ, to disruptive and the
We progress have great also made there.
a Well, setting and successful been precise our I our able done with we our in am focus was the subject more stakeholders. have move we arrived initial ever matter ourselves we successful resources to the have those both in ourselves changes, I our I for the little my the external better for that. more and the diagnostic believe achieved evaluation microarray-based And need organize already development timeframes expertise often that forward what skills solutions. be goals, expect commercialization to But to goal the to team. established leading I was reliably present than order bit to to need narrow had we ensure As had have in and success. that team complements incredible. before have goals be we confident that since I organization. simply and reliably said, just sequentially at in have of have experience We meet and making we align our developing hitting to
let So, the MosaiQ we progress review X me on the have months. last in made
from September, strong was took was ever in our European XX% milestone additional with which their importantly, sheet, an us July, milestone technical funding the the in had submission. This I balance the up achievement IH several further Mark validation funding the when for of X and detail of CEO. for in to left X was line microarray late first forward for for making dossier, when data we initial in internal head-to-head the this company. and external the a customers able we with were CE successful over months initial IH our literally began Within microarray. great the putting of strongest in supplemented months, publication team file in trial. in the documented tremendous submission of the of as we by which Later achieved Mark the history three to the million. have issued we another has This culmination as potential the part established was Fast a the timelines MosaiQ years that the secured followed the exercised very V&V at the and notes planned. of and was end was senior first And of work, in CE event that hands field time. investors warrants we key a the $XX.X study invested mid-June June, This verification field we And or trials mid-May of wrapped very
parallel. system I manufacturing the our three we over I should in They one of system microarray change a While the arrived. team X the am resulting course what of variability achieved resulting major with other months, the complexity lose brought very performance with the not pleased projects: sight last before causing delays. development elements forward in instrument, part initial some the the interdependencies This their impacting to from added in task of and of
key One the CE of the market. to variability reducing is of completed to and achieved development forward. as we development have instrument permit achievements system is And the is of we MosaiQ the that the instrument potential I months The the over in EU milestone, MosaiQ another am manufacturing of for of European the facility achievement audit going MosaiQ without thereby X audit last manufacturing in that the system Mark subject ISO conditions important month, other an October last the us to And self-certified ISO pleased milestone, XXXXX Switzerland our findings. certification on microarray of today, The regulator. report Eysins, device. to by instrument manufacturing the any a X completion effect very
its two a certification for facility the a the system. in expected of the diligence were that previously within very we quality team maybe We ISO of towards certification Mark reconfirm can start important the as implement we XX with XXXXX and what facility commercialization is tribute microarray. so is half the operate plus worked design, first the that our of can therefore So, calendar long days integrated sophisticated manufacturing first real to optimistic together CE of so hard XXXX communicated. the to year manufacturing It are be hurdles The thereafter. field most that data the
on a development adding panel V&V manufacturing content is to from perspective, And and all we the our for market-ready menu device provide leveraging track by ongoing microarray initial our to about update really this Now serological month. is with system. remain respect later an and it expansion, study disease
just the multi-modality past the be deployed. We address have question competitive introduced transfusion ones. and are capability, the diagnostics diagnostics if share in be we where commissioned most Early yielded in study, long-term amongst market? which for also the which a MosaiQ the of MosaiQ diagnostic is could findings with segments be reasons, several opportunities automated, advantage XXx variety it into effective, very for size While work the larger attractive With a it and cost much the the consider these months a important a of the else than growing to And in near of diagnostics testing laboratory portion is done market in where future. you its profitable could some fastest will to the platform molecular has more clinical beyond on market, exciting immunoassays market and broader of techniques, diagnostics December, transfusion clinical opportunity. prepared those relies we insights transfusion
of our year. development in to platform We the molecular amplification for novel we of modules, design disease for to evaluation put further also which study an with funded researcher forward third-party and a the industrial plans move hands hope the next testing sample
revolutionary independent clinical is goal screening and Our publish technique. results molecular our disease to using generate
very current up diagnostics microarray or focus ISO-certified successfully able trial system. throughput on up our it for expansion used leverage of is for in key IH and we and viable opportunity. field the filed certainly have the commit are months lastly, and to This which manufacturing Quotient. exciting then lot time must-have clinical several also So and In for European our is to important techniques the X trying is shaping encompass the while the V&V will I a to because we a alternative for repeat CE an be months key XX that, also device MosaiQ work. in with limited the donor last field microarray microarray, advancing of eventful, represent next high initial study SDS And to been for will diagnostic move it the into Mark antigens will additional XX non-transfusion element market devices a complete, deliver the myself lower phase V&V making technology testing, X relevant completed, of microarray CE are combination for MosaiQ transfusion at operating of trials. in when serological This first with to menu total completing microarray larger the the This can and to Once half demonstrate submission. disease technology are tests replace IH the once the SDS hands customer data manual throughput XXXX. the a initial dossier the of the today, our a expanded to menu manual will diagnostics both a Mark to to we transfusion near-term, MosaiQ
CE screening expanded microarray on year for tenders will as for serological device initial forward commit hope our microarray. and the Mark During will news us we compete in submission, antigen XXXX to and bring disease positive this have in evaluation menu initial to received also placement we microarray when which our calendar period, identification
So Chief call to our let me that, with Financial over Lindop, Officer. Chris? Chris hand the
